Oncology

Global Therapeutics and Syros Pharmaceuticals have teamed up to move forward to discover, develop and market novel Sickle cell disease and beta-thalassemia therapies.  Inherited blood disorders affect millions of people worldwide. As per NIH, Sickle cell disease affects around 70,000 to 80,000 Americans, whereas, Beta-thalassemia, globally affects almost 288,000 people, and is comparatively rare in America.  The collaboration will use Syros’s gene control platform for the identification of drugs and therapies inducing fetal haemoglobin, and provide the exclusive worldwide licence to Global Therapeutics for developing and commercialising the products.  ...